Exact Sciences Corporation

NasdaqCM:EXAS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🩺 Medical Instruments

💻 Telehealth

Location

United States

Market Cap

USD 9.77 B

Share Price

USD 51.81

Avg Daily Volume

2,813,723

Change (1 day)

-0.21%

Change (1 year)

17.32%

Change (YTD)

-7.80%

Exact Sciences Corporation Inventory for the year ending December 31, 2024: USD 162.38 M

Exact Sciences Corporation Inventory is USD 162.38 M for the year ending December 31, 2024, a 27.38% change year over year. Inventory is the value of goods held by a company for sale or used in the production process.

Exact Sciences Corporation Inventory for the year ending December 31, 2023 was USD 127.47 M, a 7.79% change year over year.
Exact Sciences Corporation Inventory for the year ending December 31, 2022 was USD 118.26 M, a 12.63% change year over year.
Exact Sciences Corporation Inventory for the year ending December 31, 2021 was USD 104.99 M, a 13.80% change year over year.
Exact Sciences Corporation Inventory for the year ending December 31, 2020 was USD 92.27 M, a 49.48% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Inventory	Current Assets	Property, Plant, Equipment (Net)	Total Assets

NasdaqCM: EXAS

Exact Sciences Corporation

CEO	Mr. Kevin T. Conroy J.D.
IPO Date	Feb. 1, 2001
Location	United States
Headquarters	5505 Endeavor Lane
Employees	6,900
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🩺 Medical Instruments 💻 Telehealth

Description

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.